<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712725</url>
  </required_header>
  <id_info>
    <org_study_id>3207-005</org_study_id>
    <secondary_id>2008_536</secondary_id>
    <nct_id>NCT00712725</nct_id>
  </id_info>
  <brief_title>MK3207 for Treatment of Acute Migraines (3207-005)</brief_title>
  <official_title>A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of
      MK3207 in the treatment of acute migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Freedom (PF)</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PR)</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Photophobia</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Absence of photophobia at 2 hours postdose as recorded by patient on paper diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Phonophobia</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Absence of phonophobia at 2 hours postdose as recorded by patient on paper diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Nausea</measure>
    <time_frame>2 hours postdose</time_frame>
    <description>Absence of nausea at 2 hours postdose as recorded by patient on paper diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Pain Freedom (SPF)</measure>
    <time_frame>2-24 hours postdose</time_frame>
    <description>Pain freedom (Grade 0) at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 2 to 24 hours after dosing with study medication.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3207- 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 2.5 mg</intervention_name>
    <description>Arm 1: MK3207 2.5 mg taken after migraine onset.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 5 mg</intervention_name>
    <description>Arm 2: MK3207 5 mg taken after migraine onset.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 10 mg</intervention_name>
    <description>Arm 3: MK3207 10 mg taken after migraine onset.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 20 mg</intervention_name>
    <description>Arm 4: MK3207 20 mg taken after migraine onset.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 50 mg</intervention_name>
    <description>Arm 5: MK3207 50 mg taken after migraine onset.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3207- 100 mg</intervention_name>
    <description>Arm 6: MK3207 100 mg taken after migraine onset.</description>
    <arm_group_label>6</arm_group_label>
    <other_name>MK3207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo (unspecified)</intervention_name>
    <description>Placebo taken after migraine onset.</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women from 18 to 65 years of age

          -  1+ year history of migraine that typically last from 4 to 72 hours if untreated

          -  Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months

          -  Not pregnant or planning to become pregnant in next 6 months

        Exclusion Criteria:

          -  Pregnant or breast-feeding, or planning to become pregnant in next 6 months

          -  Cannot distinguish migraine attacks from tension type headaches

          -  Migraines are mild or resolve without medication in less than 2 hours

          -  More than 15 headache-days per month or have taken medication on more than 10 days per
             month in the last 3 months

          -  Basilar type or hemiplegic migraine headaches

          -  More than 50 years old when migraines began

          -  History of cardiovascular disorder within last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 Apr;31(6):712-22. doi: 10.1177/0333102411398399. Epub 2011 Mar 7.</citation>
    <PMID>21383045</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <results_first_submitted>October 22, 2010</results_first_submitted>
  <results_first_submitted_qc>October 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2010</results_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 47 neurological and general research centers worldwide (19 in the United States and 28 internationally). The primary therapy period was between 2-Jul-08 to 16-Jan-09.</recruitment_details>
      <pre_assignment_details>Participants were assessed using the protocol inclusion and exclusion criteria at Visit 1 and, if eligible, were randomized at the same visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P2">
          <title>MK3207 2.5 mg</title>
          <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P3">
          <title>MK3207 5 mg</title>
          <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P4">
          <title>MK3207 10 mg</title>
          <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P5">
          <title>MK3207 20 mg</title>
          <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P6">
          <title>MK3207 50 mg</title>
          <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P7">
          <title>MK3207 100 mg</title>
          <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="P8">
          <title>MK3207 200 mg</title>
          <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="86"/>
                <participants group_id="P6" count="84"/>
                <participants group_id="P7" count="83"/>
                <participants group_id="P8" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P2" count="33">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P3" count="47">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P4" count="67">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P5" count="67">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P6" count="68">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
                <participants group_id="P7" count="61">One patient received study drug. The remaining patients discontinued prior to receiving study drug.</participants>
                <participants group_id="P8" count="63">The &quot;Not Completed&quot; patients discontinued prior to receiving study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Qualifying Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B2">
          <title>MK3207 2.5 mg</title>
          <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B3">
          <title>MK3207 5 mg</title>
          <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B4">
          <title>MK3207 10 mg</title>
          <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B5">
          <title>MK3207 20 mg</title>
          <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B6">
          <title>MK3207 50 mg</title>
          <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B7">
          <title>MK3207 100 mg</title>
          <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B8">
          <title>MK3207 200 mg</title>
          <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.
The participants reported in the Baseline Characteristics are randomized participants that received study treatment.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="67"/>
            <count group_id="B6" value="68"/>
            <count group_id="B7" value="62"/>
            <count group_id="B8" value="63"/>
            <count group_id="B9" value="547"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="11.2"/>
                    <measurement group_id="B2" value="43.3" spread="10.5"/>
                    <measurement group_id="B3" value="43.4" spread="11.1"/>
                    <measurement group_id="B4" value="44.1" spread="10.0"/>
                    <measurement group_id="B5" value="44.1" spread="11.3"/>
                    <measurement group_id="B6" value="42.2" spread="10.8"/>
                    <measurement group_id="B7" value="42.2" spread="10.9"/>
                    <measurement group_id="B8" value="40.5" spread="10.7"/>
                    <measurement group_id="B9" value="42.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="54"/>
                    <measurement group_id="B9" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="53"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="59"/>
                    <measurement group_id="B9" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study Region</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="43"/>
                    <measurement group_id="B9" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Freedom (PF)</title>
        <description>Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Freedom (PF)</title>
          <description>Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with PF at 2 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PR)</title>
        <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PR)</title>
          <description>Reduction of a Grade 2 or 3 severity migraine at baseline to mild or no pain (Grade 1 or 0) at 2 hours postdose.
Rating of Headache Severity (Scale from Grade 0 to 3):
Grade 0: No pain
Grade 1: Mild pain
Grade 2: Moderate pain
Grade 3: Severe pain</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with binary response PR at 2 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Photophobia</title>
        <description>Absence of photophobia at 2 hours postdose as recorded by patient on paper diary.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Photophobia</title>
          <description>Absence of photophobia at 2 hours postdose as recorded by patient on paper diary.</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="26"/>
                    <measurement group_id="O8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with Absence of Photophobia at 2 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Phonophobia</title>
        <description>Absence of phonophobia at 2 hours postdose as recorded by patient on paper diary.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Phonophobia</title>
          <description>Absence of phonophobia at 2 hours postdose as recorded by patient on paper diary.</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with Absence of Phonophobia at 2 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Nausea</title>
        <description>Absence of nausea at 2 hours postdose as recorded by patient on paper diary.</description>
        <time_frame>2 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Nausea</title>
          <description>Absence of nausea at 2 hours postdose as recorded by patient on paper diary.</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who administered study treatment, had both a baseline severity measurement and at least one postdose efficacy measurement prior to or including the 2-hour time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="41"/>
                    <measurement group_id="O8" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with Absence of Nausea at 2 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Pain Freedom (SPF)</title>
        <description>Pain freedom (Grade 0) at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 2 to 24 hours after dosing with study medication.</description>
        <time_frame>2-24 hours postdose</time_frame>
        <population>Full Analysis Set (FAS), which included all randomized participants who met the FAS criteria for PF at 2 hours postdose, and who, between 2-24 hours posedose, either 1) did not have PF at any time, 2) used rescue, or 3) answered the 24 hour recurrence question.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O2">
            <title>MK3207 2.5 mg</title>
            <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O3">
            <title>MK3207 5 mg</title>
            <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O4">
            <title>MK3207 10 mg</title>
            <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O5">
            <title>MK3207 20 mg</title>
            <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O6">
            <title>MK3207 50 mg</title>
            <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O7">
            <title>MK3207 100 mg</title>
            <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
          <group group_id="O8">
            <title>MK3207 200 mg</title>
            <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Pain Freedom (SPF)</title>
          <description>Pain freedom (Grade 0) at 2 hours postdose, with no administration of any rescue medication and no occurrence thereafter of a mild/moderate/severe headache during the 2 to 24 hours after dosing with study medication.</description>
          <population>Full Analysis Set (FAS), which included all randomized participants who met the FAS criteria for PF at 2 hours postdose, and who, between 2-24 hours posedose, either 1) did not have PF at any time, 2) used rescue, or 3) answered the 24 hour recurrence question.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="63"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value constructed from trend test of dose response, by testing the slope of the MK3207 dose covariate (all dose groups included) in a generalized linear regression model with binary response SPF 2-24 hours postdose as the dependent variable.</p_value_desc>
            <method>Generalized linear regression model</method>
            <method_desc>Model adjusted for geographic region (US, ex-US), baseline severity (moderate, severe), treatment and age (continuous), using identity link function.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were assessed for AEs from V1 (Pre-treatment Screening/Randomization) through 14 days after the dose of study medication was taken. AEs that occurred prior to administration of study medication were not included in AE summaries.</time_frame>
      <desc>Every patient is counted a single time for each applicable specific adverse event.
Patients in population are patients who took at least one tablet of the study medication.
Placebo is the pooled arm of all matching placebo doses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E2">
          <title>MK3207 2.5 mg</title>
          <description>MK3207 2.5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E3">
          <title>MK3207 5 mg</title>
          <description>MK3207 5 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E4">
          <title>MK3207 10 mg</title>
          <description>MK3207 10 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E5">
          <title>MK3207 20 mg</title>
          <description>MK3207 20 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E6">
          <title>MK3207 50 mg</title>
          <description>MK3207 50 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E7">
          <title>MK3207 100 mg</title>
          <description>MK3207 100 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
        <group group_id="E8">
          <title>MK3207 200 mg</title>
          <description>MK3207 200 mg; one orally administered dose to treat a single moderate-to-severe migraine headache.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

